STATCenter·
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Read at STAT →
Health · 1 sources covering this
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/319f8e8da6d84411efa8bb223008b74461be809c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection"></iframe>
